Drugs / BEVUFENOGENE NOFEPARVOVEC
BEVUFENOGENE NOFEPARVOVEC
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05507996 | Aug → Nov 2022 | Menkes disease | Kunming Hope of Health Hospital | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03952156 | Jun 2019 → Jan 2023 | phenylketonuria | Homology Medicines, Inc | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-06-13 | Oxford BioMedica | Regulatory Oxford Biomedica notes announcement that FDA has lifted clinical hold on Homology Medicines’ pheNIX trial oxb.com ↗
The U.S. Food and Drug Administration (FDA) has notified Homology that the clinical hold on its pheNIX gene therapy trial of HMI-102 in adults with phenylketonuria (PKU) has been lifted. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-06-13 | Oxford BioMedica | Oxford Biomedica notes announcement that FDA has lifted clinical hold on Homology Medicines’ pheNIX trial oxb.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BEVUFENOGENE NOFEPARVOVEC | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095446 ↗ |
| Known as | HMI-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03952156 ↗ |
| Known as | Recombinant adeno-associated virus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05507996 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “constructed recombinant adeno-associated virus preparation” NCT05507996 ↗ |
| Route | Intravenous | “Subjects will receive a single dose of HMI-102 administered intravenously.” NCT03952156 ↗ |